Related Experiment Video
Updated: Jun 18, 2025
05:46
Author Spotlight: Advancements in Refractive Surgical Correction for Presbyopia and Exploring Postoperative Visual Acuity
Published on: September 20, 2024
410
[Proactively addressing the challenges and issues in presbyopia correction surgery].
1Tianjin Eye Hospital, Nankai University Affiliated Eye Hospital, Clinical College of Ophthalmology of Tianjin Medical University, Tianjin Eye Institute, Tianjin Key Laboratory of Ophthalmology and Visual Science, Tianjin 300020, China.
Summary
As the population ages, presbyopia correction surgery is advancing. This review explores current procedures, challenges, and future trends to enhance safety and effectiveness for better vision outcomes.
Area of Science:
- Ophthalmology and Vision Science
- Geriatric Medicine
Context:
- The global population is aging, leading to a rise in presbyopia (age-related farsightedness).
- There is a growing demand for effective presbyopia correction methods.
- Current surgical interventions for presbyopia face unresolved challenges.
Purpose:
- To review the latest advancements in presbyopia correction surgery.
- To identify and discuss the challenges associated with current procedures.
- To outline future trends and research directions for improving presbyopia treatment.
Summary:
- This article examines various surgical techniques for presbyopia correction, highlighting innovations and persistent issues.
- It analyzes the safety, efficacy, practicality, and longevity of different approaches.
- The review aims to guide future developments in line with natural aging processes.
Impact:
- Provides a comprehensive overview of the current landscape of presbyopia correction surgery.
- Offers insights into unmet needs and areas for future research and development.
- Aims to improve patient outcomes and quality of life for individuals with presbyopia.
Related Concept Videos
01:16Focusing of Light in the Eye
2.7K
Light rays enter the eye through the cornea, a transparent dome-shaped tissue that is the eye's outermost layer. The cornea bends or refracts, light rays traveling to the pupil. The shape of the cornea determines how much of the light is bent and whether the image will be focused correctly on the retina at the back of the eye. Once the light has passed through both refraction layers, it converges into a single focal point onto a small area. This is where photoreceptors start transforming...
2.7K
01:28Angle Closure Glaucoma: Treatment
463
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
463
01:25Glaucoma: Overview
532
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
532
01:27Open Angle Glaucoma: Treatment
420
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
420